EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)

Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198)

Walid L Shaib, Rupji Manali, Yuan Liu, Bassel El-Rayes, Patrick Loehrer, Bert O'Neil, Steven Cohen, Tina Khair, Erwin Robin, Timothy Huyck, Tanios Bekaii-Saab

European Journal of Cancer · 2023-08 · 189 · 112847

DOI: 10.1016/j.ejca.2023.02.030 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2023-08. Verfasst von Walid L Shaib und 10 weiteren Autor:innen. Beteiligte Einrichtung: Winship Cancer Institute, Emory University, Atlanta, GA, USA. Electronic address: wshaib@emory.edu. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NCI NIH HHS, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAdenocarcinomaMaleHumansAntineoplastic Combined Chemotherapy ProtocolsDouble-Blind MethodVascular Endothelial Growth Factor ANeoplasm Recurrence, LocalRamucirumab

Stichwörter der Autor:innen

Disease responsePancreatic cancerPhase IIRCTSurvival

Substanzen

Vascular Endothelial Growth Factor ARamucirumab

Autor:innen und Institutionen

  • Winship Cancer Institute, Emory University, Atlanta, GA, USA. Electronic address: wshaib@emory.edu.
  • Department of Biostatistics, Emory University, Atlanta, GA, USA.
  • Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, USA.
  • Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA.
  • Gettysburg Cancer Center, Pennsylvania Cancer Specialists, PA, USA.

Förderung

  • NCI NIH HHS
  • Eli Lilly and Company

Zitieren

APA

Shaib, W. L., Manali, R., Liu, Y., El-Rayes, B., Loehrer, P., O'Neil, B., Cohen, S., Khair, T., Robin, E., Huyck, T., & Bekaii-Saab, T. (2023). Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). European Journal of Cancer, 189, 112847. https://doi.org/10.1016/j.ejca.2023.02.030

Vancouver

Shaib WL, Manali R, Liu Y, El-Rayes B, Loehrer P, O'Neil B, et al. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). European Journal of Cancer. 2023;189:112847. doi:10.1016/j.ejca.2023.02.030

BibTeX
@article{Shaib2023,
  author = {Shaib, Walid L and Manali, Rupji and Liu, Yuan and El-Rayes, Bassel and Loehrer, Patrick and O'Neil, Bert and Cohen, Steven and Khair, Tina and Robin, Erwin and Huyck, Timothy and Bekaii-Saab, Tanios},
  title = {Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198)},
  journal = {European Journal of Cancer},
  year = {2023},
  volume = {189},
  pages = {112847},
  doi = {10.1016/j.ejca.2023.02.030}
}
Kostenlos starten →